Julian D. Sandbrink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julian D. Sandbrink has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Brian David Earp
National University of Singapore
2 shared publications - Ivar Rodriguez Hannikainen
Department of Philosophy I, University of Granada, Granada, Spain
2 shared publications - Christopher Register
University of Oxford
1 shared publication - Daniel Villiger
Institute of Philosophy, University of Zurich, Zurich, Switzerland
1 shared publication David Bryce Yaden
Johns Hopkins University School of Medicine
1 shared publication- David Bryce Yaden
Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, United States of America
1 shared publication
Latest Publications
- Open Access
- 27 July 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Advancing data protections for implantable brain-computer interfaces
- 27 July 2026
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Open AccessAdvancing data protections for implantable brain-computer interfaces
- Open Access
- 8 September 2025
- Published by Taylor & Francis in Philosophical Psychology
- Vol. 38 (7) , 3340-3383
Psychedelics beyond medicine: Treatment, enhancement, hype, consent, and the limits of medicalization
- 8 September 2025
- Published by Taylor & Francis in Philosophical Psychology
- Vol. 38 (7) , 3340-3383
Open AccessPsychedelics beyond medicine: Treatment, enhancement, hype, consent, and the limits of medicalization
- Open Access
- 5 February 2024
- Published by Taylor & Francis in AJOB Neuroscience
- Vol. 15 (2) , 82-89
Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists
The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.
- 5 February 2024
- Published by Taylor & Francis in AJOB Neuroscience
- Vol. 15 (2) , 82-89
Open AccessStrong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists
The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.